Carregant...
Emerging novel therapies in the treatment of castrate-resistant prostate cancer
The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review takes...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Canadian Medical Association
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3104424/ https://ncbi.nlm.nih.gov/pubmed/21470540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.10160 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|